Nine companies came public this week raising a combined $1.1 billion, plus one blank check company. The week's three largest expected IPOs postponed. All but two companies priced below the target midpoint. Enterprise tech darlings SailPoint and...read more
scPharmaceuticals, which is commercializing an injectable version of an intravenous drug for heart failure, raised $90 million by offering 6.4 million shares at $14, the low end of the range of $14 to $16. scPharmaceuticals plans to list on the Nasdaq under the...read more
Following the busiest week of 2017, the week ahead will be another record breaker with 12 IPOs scheduled to raise a combined $2.1 billion. The week will be led by automated email platform SendGrid and cybersecurity...read more
scPharmaceuticals, which is commercializing an injectable version of an intravenous drug for heart failure, announced terms for its IPO on Tuesday. The Burlington, MA-based company plans to raise $96 million by offering 6.4 million shares at a price range...read more
US IPO Weekly Recap: 9 IPOs in final feast before Thanksgiving
Nine companies came public this week raising a combined $1.1 billion, plus one blank check company. The week's three largest expected IPOs postponed. All but two companies priced below the target midpoint. Enterprise tech darlings SailPoint and...read more
Injectable drug developer scPharmaceuticals prices IPO at $14 low end
scPharmaceuticals, which is commercializing an injectable version of an intravenous drug for heart failure, raised $90 million by offering 6.4 million shares at $14, the low end of the range of $14 to $16. scPharmaceuticals plans to list on the Nasdaq under the...read more
US IPO Week Ahead: Back-to-back record activity with 12 IPOs set to price
Following the busiest week of 2017, the week ahead will be another record breaker with 12 IPOs scheduled to raise a combined $2.1 billion. The week will be led by automated email platform SendGrid and cybersecurity...read more
Injectable drug developer scPharmaceuticals sets terms for $96 million IPO
scPharmaceuticals, which is commercializing an injectable version of an intravenous drug for heart failure, announced terms for its IPO on Tuesday. The Burlington, MA-based company plans to raise $96 million by offering 6.4 million shares at a price range...read more